Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Affiliations

• ¹ Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
• ² Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston.
• ³ Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna.
• ⁴ Centre Hospitalier Universitaire de Québec - Université Laval and Faculty of Pharmacy, Université Laval, Québec.
• ⁵ Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna.
• ⁶ UMR CANTHER, INSERM 1277-CNRS 9020 UMRS 12. University of Lille, Hematology Laboratory, Biology and pathology center, CHU de Lille, 59000 Lille.
• ⁷ Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC1405, Clermont Ferrand.
• ⁸ 3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna.
• ⁹ 1. Medical Department, Center for Oncology and Hematology, Wilhelminenhospital Vienna, Vienna.
• ¹⁰ Department of Laboratory Medicine, Medical University of Vienna.
• ¹¹ Department of Medicine I, Division of Oncology, Medical University of Vienna.
• ¹² Clinical Department of Pathology, Medical University of Vienna.
• ¹³ Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna. philipp.staber@meduniwien.ac.at.